Golden age of domestic biopharmaceutical products, pouring foreign entries
At the beginning of the year, foreign expansion of domestic biopharmaceutical products has produced results. While technology of the anemia treatment being developed by Chong Kun Dang is exported, Samsung Bioepis acquired European approval to sell its Enbrel biosimilar.
On the 17th, Samsung Bioe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
